Cytokine Elevation in Sudden Death With Respiratory Syncytial Virus: A Case Report of 2 Children
In this report, we present 2 RSV-related deaths of children who were born at full-term and developed normally up to the age of 19 months. Their cardiopulmonary arrests occurred within half a day after the onset of symptoms, such as cough and high fever. Many postmortem examinations were performed to investigate their unexpected deaths. Histopathological examinations revealed extensive bronchiolitis and mild pneumonia accompanying airway obstruction. Immunostaining revealed the presence of the virus mainly in bronchial epithelia, but not in alveoli. Complete brain edema was prominent, and encephalopathy was developing. Blood tests revealed that the IL-6 level was elevated more than>200-fold above normal, despite a normal C-reactive protein level. Because IL-6 may reflect the severity of bronchial epithelial damage and contribute to brain edema, an extreme elevation of IL-6 may predict the risk for sudden death in children with RSV infection.
Pneumonia is the most common cause of hospitalization for nursing home residents. When deciding whether to treat a resident in the nursing home or transfer to a hospital, it is important to consider risks of hospitalization, including significant functional decline. Little is known about the functional status outcomes of nursing home residents hospitalized for pneumonia.
Background Streptococcus pneumonia is a significant cause of morbidity and mortality in adults who are immunocompromised and of advanced age. It is the standard of care to vaccinate all high-risk adults (18-64 years) and adults 65 years and older with 2 pneumococcal vaccines. However, pneumococcal immunization rates remain below the HealthyPeople2020 target goal of 90% nationally and locally.
Pneumonia is one of the most common infections identified in nursing home residents and has the highest mortality rate, yet the diagnosis and appropriate treatment can remain elusive due to its “atypical presentation” and lack of studies of antibiotic treatment.
Publication date: Available online 25 February 2020Source: Mutation Research/Genetic Toxicology and Environmental MutagenesisAuthor(s): Yu Gao, Ping Wang, Yinping Su, Zhaonan Wang, Lin Han, Jie Li, Yinghua Fu, Fengling Zhao, Quanfu Sun, Yumin Lyu
Publication date: Available online 25 February 2020Source: The Lancet Respiratory MedicineAuthor(s): Jaclyn A Smith, Michael M Kitt, Alyn H Morice, Surinder S Birring, Lorcan P McGarvey, Mandel R Sher, Yu-Ping Li, Wen-Chi Wu, Zhi Jin Xu, David R Muccino, Anthony P Ford, Jaclyn Smith, Lorcan McGarvey, Surinder Birring, James Hull, Warner W Carr, Alan B Goldsobel, Gary N Gross, John R Holcomb, Iftikhar Hussain
Publication date: Available online 25 February 2020Source: The Lancet Respiratory MedicineAuthor(s): Richard S Irwin, Cynthia L French, J Mark Madison
Publication date: 1 June 2020Source: Personality and Individual Differences, Volume 159Author(s): Donald H. Saklofske
Authors: Stancu IC, Ferraiolo M, Terwel D, Dewachter I Abstract Tau is most intensely studied in relation to its executive role in Tauopathies, a family of neurodegenerative disorders characterized by the accumulation of Tau aggregates [15, 21, 38, 75, 89, 111, 121, 135, 175, 176, 192]. Tau aggregation in the different Tauopathies differs in the affected cell type, the structure of aggregates and Tau isoform composition. However, in all Tauopathies, accumulation of pathological Tau in well-characterized and well-defined brain regions, correlates strongly with symptoms associated with the dysfunction of this brain r...
The trial was funded by the drug's maker, Merck, and involved 253 American and British participants. All had suffered from an unexplained or untreatable cough that had lasted for an average of almost 15 years.